Patients with AXL gene alterations were also recruited for another phase I study to determine the safety, tolerability, pharmacokinetics, and anti-tumor effects induced by Mipasetamab Uzoptirine (ADCT-601) alone, or in combination with other anti-cancer drugs (NCT05389462). The gene discussed is AXL; the disease is cancer.